or
Bookmark and Share
Process for the formation of human-human hybridoma
   
Document Number
US Patent 4916072
Issued Date
April 10, 1990
Link
Inventors
Map
Abstract
A human-human hybridoma is formed by subjecting a transformed human cell to a proliferaton inhibitory treatment and then fusing the thus-treated human cell with a human antibody producing cell. A desired clone may be selected from the resultant fused cells by using an anti-HLA antibody.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
2
Comments:
no comments yet
Owner
Published
April 10, 1990
Application Number
07/031,671
Filed
March 30, 1987
US Classification
530/388.15   435/343.1 435/70.21 435/948 530/388.73 530/388.75 530/388.8 530/809 530/865
Int'l Classification
C07K   16/18   (20060101)   C07K   16/00   (20060101)   C07K   16/30   (20060101)  
Assistant Examiner
Priority Data
Mar 28, 1986 [JP] 61-70199
USPTO Field of Search
435/172.2   435/240.26   435/240.27   435/68   435/948   530/387   935/809   935/90   935/100  
Related Patents
5534430 - Cell strain capable of multiplying an Epstein-Barr virus - Owned by Hitachi Chemical Company Limited (Tokyo,JP)

The present invention relates to a cell strain capable of separating and multiplying an EB virus and derived from human lymphocyte cancer cells and a method of separating and multiplying the EB virus by means of said cell strain. The present cell strain can be applied to the separation and multiplication of the wild type virus present in various places, as well as to the separation and multiplication of the virus produced by homologous recombination etc. The virus newly separated and multiplied can be applied to vaccine etc. For the more efficient separation and multiplication of the virus, several markers can be inserted into the present cell strain.

7220559 - Development of human monoclonal antibodies and uses thereof - Owned by The Trustees of Columbia University in the City of New York (New York, NY)

This invention provides: a heteromyeloma, other than B6B11, capable of producing a trioma when fused with a human lymphoid cell, wherein the trioma is capable of producing a monoclonal antibody-secreting tetroma when fused with a second, antibody-secreting human lymphoid cell; a trioma fusion partner which does not produce antibody, obtained by fusing a heteromyeloma which does not produce antibody with a human lymphoid cell; a monoclonal antibody-secreting tetroma, obtained by fusing a trioma which does not produce antibody with an antibody-secreting human lymphoid cell; a method of producing a monoclonal antibody that specifically recognizes an antigen associated with a condition; a method of identifying an antigen associated with a condition using the trioma fusion partner; a method of diagnosing a condition using the trioma fusion partner; a method for preventing a condition; and compositions and therapeutic compositions comprising monoclonal antibodies produced using the trioma fusion partner.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us